This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2004 Sep;40(14):2016-21.

doi: 10.1016/j.ejca.2004.02.018.

Targeted therapy--how successful has it been?

PMID: 15341973
DOI: 10.1016/j.ejca.2004.02.018

Editorial

Targeted therapy--how successful has it been?

Ch Dittrich. Eur J Cancer. 2004 Sep.

. 2004 Sep;40(14):2016-21.

doi: 10.1016/j.ejca.2004.02.018.

Author

PMID: 15341973
DOI: 10.1016/j.ejca.2004.02.018

No abstract available

PubMed Disclaimer

Comment on

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS. Verweij J, et al. Eur J Cancer. 2003 Sep;39(14):2006-11. Eur J Cancer. 2003. PMID: 12957454 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science